Abivax (NASDAQ:ABVX) Shares Down 5.4% – Here’s Why

Abivax SA Sponsored ADR (NASDAQ:ABVX) shares traded down 5.4% during trading on Tuesday . The company traded as low as $125.01 and last traded at $125.7350. 578,486 shares were traded during mid-day trading, a decline of 56% from the average session volume of 1,301,227 shares. The stock had previously closed at $132.91.

Analysts Set New Price Targets

ABVX has been the subject of a number of research analyst reports. Oppenheimer set a $131.00 price objective on Abivax in a report on Thursday, January 8th. Piper Sandler reissued an “overweight” rating and set a $142.00 price target on shares of Abivax in a report on Tuesday, December 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Abivax in a research note on Wednesday, January 21st. Wedbush initiated coverage on Abivax in a research report on Tuesday. They set an “outperform” rating and a $110.00 price objective on the stock. Finally, Wall Street Zen downgraded shares of Abivax from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $134.75.

Abivax Stock Down 3.8%

The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.86 and a current ratio of 7.86. The company has a market capitalization of $10.11 billion, a P/E ratio of -30.53 and a beta of 0.81. The firm’s fifty day moving average is $123.45 and its 200-day moving average is $104.84.

Abivax (NASDAQ:ABVX) last issued its quarterly earnings results on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The firm had revenue of ($4.92) million for the quarter. As a group, equities research analysts predict that Abivax SA Sponsored ADR will post -2.83 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ABVX. Bank of America Corp DE grew its stake in shares of Abivax by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after acquiring an additional 1,990 shares during the last quarter. Cubist Systematic Strategies LLC increased its stake in Abivax by 34.3% during the 1st quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock valued at $63,000 after purchasing an additional 2,595 shares in the last quarter. Millennium Management LLC raised its holdings in Abivax by 6.0% in the first quarter. Millennium Management LLC now owns 987,414 shares of the company’s stock worth $6,171,000 after buying an additional 56,235 shares during the last quarter. Woodline Partners LP lifted its stake in shares of Abivax by 319.5% in the first quarter. Woodline Partners LP now owns 201,924 shares of the company’s stock worth $1,262,000 after buying an additional 153,788 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Abivax during the second quarter valued at approximately $139,000. Hedge funds and other institutional investors own 47.91% of the company’s stock.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.